Robert Michael Dudley - 12 Dec 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol: RNAZ
Transactions as of: 12 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 14 Dec 2022, 19:11:57 UTC
Previous filing: 16 Sep 2022
Next filing: 19 May 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAZ	Stock Option (Right to Buy)	Award	$0	+135,000		$0.000000	135,000	12 Dec 2022	Common Stock	135,000	$0.5100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.

Content

Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.